Skip to content

Moderna Shares Rise On Earnings, Revenue Beat

Analyst Team trader
Updated 3 Aug 2022

Buy Moderna Shares Your Capital Is At Risk

Key points:

  • Moderna reports second quarter earnings
  • The drugmaker topped analyst estimates
  • Moderna shares have gained more than 3% premarket

Moderna shares are up premarket after the company reported second-quarter earnings before the open Wednesday, August 3rd, topping earnings and revenue estimates.

The drugmaker posted earnings per share of $5.24 on revenue of $4.7 billion. Analysts expected earnings of $4.55 per share on revenue of $4.07 billion.

The company's revenue rise was put down to increased product sales from sales of its COVID-19 vaccine.


Also Read: Five Best Pharmaceutical Stocks To Watch In 2022

Moderna reiterated advance purchase agreements for expected delivery in 2022 of approximately $21 billion, while it also announced a new $3 billion share repurchase plan.

Moderna shares are trading 3.85% higher premarket, following the report.

“Today’s earnings represent a strong second quarter performance, with $10.8 billion in revenue for the first half of the year. We continue to have advance purchase agreements for expected delivery in 2022 of around $21 billion of sales. Given our strong financial position and commercial momentum, we are announcing today that the Board of Directors has approved a new share repurchase program for $3 billion,” said Stéphane Bancel, Chief Executive Officer of Moderna.

“Despite the slowing economy and challenges in the biotech industry, Moderna is in a unique position: a platform to drive scale and speed in research of new medicines, a strong balance sheet with $18 billion of cash and an agile, mission-driven team of over 3,400 people and growing,” added Bancel.

The AskTraders Analyst Team features experts in technical and fundamental analysis, as well as traders specializing in stocks, forex, and cryptocurrency.